Bayer AG

As of June 30, 2026, Bayer AG carries a market capitalization of 764.62B, placing it among publicly traded companies globally. Its enterprise value stands at 665.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bayer AG's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Bayer AG has 982.42M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.84, and the price-to-book ratio stands at 1.29.

As of June 30, 2026, Bayer AG trades at an EV/EBITDA multiple of 2.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 665.66B versus a market cap of 764.62B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bayer AG maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bayer AG posted a negative return on equity (ROE) of -5.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.64, reflecting losses generated across the asset base. The company generates approximately 10.15M in revenue per employee across its workforce of 89,262.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.54 indicates how many times Bayer AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bayer AG recorded 9.78B in income tax expense. The company reported a pretax loss of -24.41B and -34.69B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bayer AG's stock has gained approximately 62.55% over the past 52 weeks. The 50-day moving average sits at 857.83, while the 200-day moving average is 665.34.

Over the twelve months ended June 30, 2026, Bayer AG generated 905.72B in revenue and converted that into -34.69B in net income, yielding earnings per share of -34.80. EBITDA reached 237.69B, while operating income came in at 162.82B.

These figures are as of June 30, 2026. Total book value stands at 590.52B, with working capital of 27.43B providing operational flexibility.

Bayer AG produced 95.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -53.99B in capital expenditures, free cash flow totaled 41.48B - equivalent to 42.22 per share.

Over the twelve months ended June 30, 2026, Bayer AG posted a gross margin of 59.05, reflecting its pricing power and cost economics. The operating margin of 17.98 and net profit margin of -3.83 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bayer AG paid dividends of 2.66 per share. The dividend payout ratio of -7.76 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bayer AG shareholders.

Bayer AG's most recent stock split took place on June 18, 2018 with a 495:503 split ratio.